Since the mid‐1990s, significant advances in pharmacological management strategies of T2DM have been made; namely Metformin (Bailey, 2017) and novel insulin analogs (Quianzon & Cheikh, 2012). The gene discussed is INS; the disease is type 2 diabetes mellitus.